purpose evaluate tumor normal tissue dosimetry NUMBER cobalt gray equivalent cge x NUMBER fraction proton radiotherapy schedule initiating clinical trial neoadjuvant proton radiotherapy pancreatic adenocarcinoma methods materials NUMBER pancreatic cancer patients treated neoadjuvant radiotherapy NUMBER gy x NUMBER massachusetts general hospital treatment plans generated using NUMBER cge x NUMBER fraction proton regimen facilitate dosimetric comparisons clinical target volumes normal tissue volumes held constant plans optimized target volume coverage normal tissue sparing results hypofractionated proton conventionally fractionated radiotherapy plans provided acceptable target volume coverage dose homogeneity improved dose conformality provided hypofractionated proton regimen resulted significant sparing kidneys liver small bowel evidenced significant reductions mean doses expressed percentage prescribed dose structures kidney liver sparing evident regions NUMBER prescribed dose kidneys NUMBER prescribed dose liver improvements dosimetry observed regions mean stomach duodenum doses expressed percentage prescribed dose similar techniques conclusions proton radiotherapy schedule consisting NUMBER fractions NUMBER cge neoadjuvant therapy adenocarcinoma pancreas dosimetrically feasible providing excellent target volume coverage dose homogeneity normal tissue sparing hypofractionated proton radiotherapy setting merits phase clinical trial investigation short course intensity modulated intensity modulated low dose small bowel high low dose